ACRO BIOMEDICAL CO., LTD.

2020 Q4 Form 10-Q Financial Statement

#000164033420002867 Filed on November 17, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.12K $160.00 $1.470K
YoY Change 1891.21% -89.12% 27.83%
Cash & Equivalents $18.12K $156.00 $1.472K
Short-Term Investments
Other Short-Term Assets $17.23K $16.00K $7.990K
YoY Change 100.25% -97.58%
Inventory $938.0K $938.0K $1.060M
Prepaid Expenses $1.000K $4.000K
Receivables
Other Receivables
Total Short-Term Assets $973.4K $954.2K $1.069M
YoY Change 10.67% -10.78% -27.63%
LONG-TERM ASSETS
Property, Plant & Equipment $24.70K $30.72K
YoY Change -49.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.230K $0.00
YoY Change -100.0%
Total Long-Term Assets $24.70K $34.95K $0.00
YoY Change -53.09% -100.0%
TOTAL ASSETS
Total Short-Term Assets $973.4K $954.2K $1.069M
Total Long-Term Assets $24.70K $34.95K $0.00
Total Assets $998.1K $989.1K $1.069M
YoY Change 7.07% -7.51% -27.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.00K $5.070K $18.02K
YoY Change -16.07% -71.86% 146.51%
Accrued Expenses $24.50K $26.85K
YoY Change 2.25%
Deferred Revenue
YoY Change
Short-Term Debt $243.0K $188.0K $61.77K
YoY Change 824.47% 204.31%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $312.2K $239.9K $195.8K
YoY Change 179.88% 22.52% -18.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $3.730K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $3.730K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $312.2K $239.9K $195.8K
Total Long-Term Liabilities $0.00 $3.730K $0.00
Total Liabilities $312.2K $243.6K $195.8K
YoY Change 133.17% 24.43% -18.65%
SHAREHOLDERS EQUITY
Retained Earnings -$238.7K -$176.9K
YoY Change 96.91%
Common Stock $924.5K $922.4K
YoY Change 0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $685.9K $745.5K $873.7K
YoY Change
Total Liabilities & Shareholders Equity $998.1K $989.1K $1.069M
YoY Change 7.07% -7.51% -27.88%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
ACRO BIOMEDICAL CO., LTD.
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26847 USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48425 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37607 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1472 USD
CY2020Q3 acbm Purchase Deposit For Inventory
PurchaseDepositForInventory
12000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001622996
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
879471 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30721 USD
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47760000 shares
CY2019Q4 us-gaap Liabilities
Liabilities
133887 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156 USD
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
911 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23834 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
938000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
878560 USD
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Assets Current
AssetsCurrent
954156 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23964 USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2020Q3 us-gaap Security Deposit
SecurityDeposit
4230 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3734 USD
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
4230 USD
CY2020Q3 us-gaap Liabilities
Liabilities
243623 USD
CY2020Q3 us-gaap Assets
Assets
989107 USD
CY2019Q4 us-gaap Assets
Assets
932126 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5072 USD
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
20000 USD
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
37464 USD
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
187970 USD
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
26279 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
239889 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
111541 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22346 USD
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
798239 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
932126 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
687964 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
874607 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
871680 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
745484 USD
us-gaap Cost Of Revenue
CostOfRevenue
528560 USD
us-gaap Gross Profit
GrossProfit
159404 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71541 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64460 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
212159 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
347318 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
71541 USD
us-gaap Operating Expenses
OperatingExpenses
212159 USD
us-gaap Operating Expenses
OperatingExpenses
347318 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47760000 shares
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
45000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-73099 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-65286 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-55682 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-64460 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-52755 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-347318 USD
CY2020Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1558 USD
CY2019Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
826 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2927 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1543 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1558 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-826 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2927 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1543 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-348861 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9871 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-53130 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73099 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-75157 USD
us-gaap Net Income Loss
NetIncomeLoss
-55682 USD
us-gaap Net Income Loss
NetIncomeLoss
-295731 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
-2927 USD
acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
-1543 USD
CY2020Q3 acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
-1558 USD
CY2019Q3 acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
-826 USD
acbm Increase Decrease In Right Of Use Asset And Lease Liability
IncreaseDecreaseInRightOfUseAssetAndLeaseLiability
1975 USD
CY2020Q3 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
1558 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
81116 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
63699 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-169750 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-50824 USD
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47760000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47760000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47760000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
47760 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
47760 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176883 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121201 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
879796 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
817025 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1167860 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
998218 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
948003 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
873672 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
989107 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
64460 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-71541 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47760000 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47760000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47760000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47760000 shares
CY2020Q1 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
441 USD
CY2020Q2 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
928 USD
CY2019Q1 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
108 USD
CY2019Q2 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
609 USD
CY2019Q3 acbm Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans
826 USD
us-gaap Share Based Compensation
ShareBasedCompensation
148395 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-19941 USD
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-73071 USD
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
59440 USD
acbm Increase Decrease In Purchase Deposit For Inventory
IncreaseDecreaseInPurchaseDepositForInventory
12000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-18762 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-19156 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17464 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162446 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94637 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
161691 USD
acbm Operating Losses Utilized
OperatingLossesUtilized
11078 USD
acbm Operating Losses Utilized
OperatingLossesUtilized
23407 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10442 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
116000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-755 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-36135 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
19156 USD
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11693 USD
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-73261 USD
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50326 USD
CY2020Q3 acbm Operating Leases Imputed Interest
OperatingLeasesImputedInterest
706 USD

Files In Submission

Name View Source Status
0001640334-20-002867-index-headers.html Edgar Link pending
0001640334-20-002867-index.html Edgar Link pending
0001640334-20-002867.txt Edgar Link pending
0001640334-20-002867-xbrl.zip Edgar Link pending
acbm-20200930.xml Edgar Link completed
acbm-20200930.xsd Edgar Link pending
acbm-20200930_cal.xml Edgar Link unprocessable
acbm-20200930_def.xml Edgar Link unprocessable
acbm-20200930_lab.xml Edgar Link unprocessable
acbm-20200930_pre.xml Edgar Link unprocessable
acbm_10q.htm Edgar Link pending
acbm_ex311.htm Edgar Link pending
acbm_ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending